0000000000235420

AUTHOR

Csaba Farsang

showing 6 related works from this author

Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE s…

2010

AimsLimited information is available on office and ambulatory blood pressure (BP) control as well as on cardiovascular (CV) risk profile in treated hypertensive patients living in central and eastern European countries.Methods and resultsIn 2008, a survey on 7860 treated hypertensive patients followed by non-specialist or specialist physicians was carried out in nine central and eastern European countries (Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia, and Ukraine). Cardiovascular risk assessment was based on personal history, clinic BP values, as well as target organ damage evaluation. Patients had a mean (±SD) age of 60.1 ± 11 years, and the majority of them …

Malemedicine.medical_specialtyAmbulatory blood pressureCross-sectional studyRisk AssessmentRisk FactorsInternal medicinemedicineAlbuminuriaHumansBlood pressure cardiovascular risk risk factors hypertensionEurope EasternStrokeAntihypertensive AgentsAgedbusiness.industryMiddle Agedmedicine.diseaseSurgeryEastern europeanEuropeBlood pressureCross-Sectional StudiesCardiovascular DiseasesAmbulatoryHypertensionElectrocardiography AmbulatoryMicroalbuminuriaDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineRisk assessmentbusinessEuropean heart journal
researchProduct

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive tre…

2016

medicine.medical_specialtyPhysiologybusiness.industry030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineBlood pressureSprintShot (pellet)Internal MedicinePhysical therapyMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessStrokeJournal of hypertension
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

2009

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Commit

medicine.medical_specialtymanagement arterial hypertensionPhysiologyupdateRenal functionBlood PressureInternal medicinemedicineInternal MedicineHumanscardiovascular diseasesAntihypertensive AgentsTask forcebusiness.industryHypertension GuidelineHypertension managementGeneral MedicineEuropeOrgan damageBlood pressureHypertensionPractice Guidelines as Topiccardiovascular systemCardiologyMED/09 - MEDICINA INTERNAbusinessEndothelin receptorCardiology and Cardiovascular Medicine
researchProduct